Cerus Corporation has secured a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the United States, covering the entire INTERCEPT product line—including the INTERCEPT Blood System for platelets, plasma, and the cryoprecipitated fibrinogen complex (IFC). The deal gives BCA member blood centers the right to produce and distribute INTERCEPT products to their hospital customers, creating a new channel for Cerus’s pathogen‑reduction technology.
BCA operates more than 60 independent community blood centers that collectively supply about 50% of the nation’s blood products. By partnering with BCA, Cerus gains access to a broad base of community blood centers that already serve a large portion of the U.S. transfusion market, positioning the company to accelerate adoption of its INTERCEPT platform, particularly the high‑growth IFC product.
Cerus’s Q3 2025 results provide context for the partnership’s potential impact. Total revenue reached $60.2 million, up 15% year‑over‑year, with product revenue of $52.7 million. IFC sales surged 110% to $3.9 million, reflecting strong demand for pathogen‑reduced plasma. The company posted positive non‑GAAP adjusted EBITDA of $5 million for the quarter and raised its full‑year 2025 product revenue guidance to $202 million–$204 million, up from the prior guidance of $202 million–$204 million, signaling confidence in continued growth.
Management emphasized the strategic importance of the BCA partnership. CEO William “Obi” Greenman highlighted that INTERCEPT adoption in the U.S. has reached the mid‑60% range and that the partnership will help expand IFC usage. COO Vivek Jayaraman expressed excitement about leveraging BCA’s resource‑sharing model to accelerate product penetration, while BCA CEO Bill Block underscored the critical role of pathogen inactivation in modern blood safety.
The agreement is expected to broaden Cerus’s market reach, increase product penetration, and support the company’s trajectory of revenue growth and margin improvement as it scales its pathogen‑reduction technology across a larger network of blood centers and hospitals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.